Literature DB >> 25963933

[Hyponatremia and tolvaptan : what is the situation 5 years after approval?].

J Hensen1.   

Abstract

The diuretic tolvaptan has been approved for more than 5 years for the indications of euvolemic hyponatremia due to syndrome of inappropriate antidiuretic hormone (SIADH) secretion. In recent years many patients have been treated with tolvaptan and many physicians could gather practical experience. Other countries, such as the USA had already gained greater experience, also in the indications for hypervolemic hyponatremia. After approval was granted more than 5000 patients worldwide were included in the so-called hyponatremia register and 22 active centers in Germany with 317 patients participated. Although some details from this now concluded register have been published, the final publication of the multinational post-authorization safety study on tolvaptan in the treatment of SIADH has not yet been published. In the years 2012 and 2013 two warning letters were issued on tolvaptan. The first letter warned of the risk of a faster increase in serum sodium using tolvaptan and provided detailed information on how the risk of osmotic demeyelination can be minimized. So far only one proven case of osmotic demelination syndrome (ODS) is known; however, this occurred following incorrect use of tolvaptan in a monotherapy. The second warning letter provided information on the potential risk (reversible) of liver damage by tolvaptan, which resulted from the TEMPO 3:4 study. In this study tolvaptan was used in a higher dosage for therapy of autosomal dominant polycystic kidney disease. Although the European renal best practice (ERBP) guidelines from 2014 did not recommend tolvaptan for the indications of SIADH, other guidelines came to different conclusions. In summary, 5 years after the approval of tolvaptan there is still no consensus. At the current time many questions still remain unanswered. Initiation of therapy with tolvaptan remains reserved for experienced physicians in hospitals. Treatment must be adapted on the basis of a clinical estimation of the individual situation of each patient.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25963933     DOI: 10.1007/s00108-015-3675-2

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  24 in total

1.  Investigation and management of severe hyponatraemia in a hospital setting.

Authors:  M S B Huda; A Boyd; K Skagen; D Wile; C van Heyningen; I Watson; S Wong; G Gill
Journal:  Postgrad Med J       Date:  2006-03       Impact factor: 2.401

2.  Urea for hyponatremia?

Authors:  Richard H Sterns; Stephen M Silver; John K Hix
Journal:  Kidney Int       Date:  2015-02       Impact factor: 10.612

Review 3.  Review and analysis of differing regulatory indications and expert panel guidelines for the treatment of hyponatremia.

Authors:  Joseph G Verbalis; Ashley Grossman; Charlotte Höybye; Isabelle Runkle
Journal:  Curr Med Res Opin       Date:  2014-05-14       Impact factor: 2.580

Review 4.  The syndrome of inappropriate secretion of antidiuretic hormone.

Authors:  F C Bartter; W B Schwartz
Journal:  Am J Med       Date:  1967-05       Impact factor: 4.965

5.  Oral tolvaptan is safe and effective in chronic hyponatremia.

Authors:  Tomas Berl; Friederike Quittnat-Pelletier; Joseph G Verbalis; Robert W Schrier; Daniel G Bichet; John Ouyang; Frank S Czerwiec
Journal:  J Am Soc Nephrol       Date:  2010-02-25       Impact factor: 10.121

6.  Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations.

Authors:  Joseph G Verbalis; Steven R Goldsmith; Arthur Greenberg; Cynthia Korzelius; Robert W Schrier; Richard H Sterns; Christopher J Thompson
Journal:  Am J Med       Date:  2013-10       Impact factor: 4.965

7.  Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.

Authors:  Marvin A Konstam; Mihai Gheorghiade; John C Burnett; Liliana Grinfeld; Aldo P Maggioni; Karl Swedberg; James E Udelson; Faiez Zannad; Thomas Cook; John Ouyang; Christopher Zimmer; Cesare Orlandi
Journal:  JAMA       Date:  2007-03-25       Impact factor: 56.272

8.  Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia.

Authors:  E Dahl; L L Gluud; N Kimer; A Krag
Journal:  Aliment Pharmacol Ther       Date:  2012-08-21       Impact factor: 8.171

9.  Tolvaptan in patients with autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Arlene B Chapman; Olivier Devuyst; Ron T Gansevoort; Jared J Grantham; Eiji Higashihara; Ronald D Perrone; Holly B Krasa; John Ouyang; Frank S Czerwiec
Journal:  N Engl J Med       Date:  2012-11-03       Impact factor: 91.245

10.  Treatment of euvolemic hyponatremia in the intensive care unit by urea.

Authors:  Guy Decaux; Caroline Andres; Fabrice Gankam Kengne; Alain Soupart
Journal:  Crit Care       Date:  2010-10-14       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.